|
1
|
Jemal A, Murray T, Ward E, et al: Cancer
statistics, 2005. CA Cancer J Clin. 1:10–30. 2005. View Article : Google Scholar
|
|
2
|
Cohen Y, Xing M, Mambo E, et al: BRAF
mutation in papillary thyroid carcinoma. J Natl Cancer Inst.
8:625–627. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Wilhelm SM, Carter C, Tang L, et al: BAY
43-9006 exhibits broad spectrum oral antitumor activity and targets
the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in
tumor progression and angiogenesis. Cancer Res. 19:7099–7109. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Preto A, Goncalves J, Rebocho AP, et al:
Proliferation and survival molecules implicated in the inhibition
of BRAF pathway in thyroid cancer cells harbouring different
genetic mutations. BMC Cancer. 1:3872009. View Article : Google Scholar
|
|
5
|
Cho NY, Choi M, Kim BH, Cho YM, Moon KC
and Kang GH: BRAF and KRAS mutations in prostatic adenocarcinoma.
Int J Cancer. 8:1858–1862. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Chong H, Vikis HG and Guan KL: Mechanisms
of regulating the Raf kinase family. Cell Signal. 5:463–469. 2003.
View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Davies H, Dicks E, Stephens P, et al: High
throughput DNA sequence variant detection by conformation sensitive
capillary electrophoresis and automated peak comparison. Genomics.
3:427–432. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Kimura ET, Nikiforova MN, Zhu Z, Knauf JA,
Nikiforov YE and Fagin JA: High prevalence of BRAF mutations in
thyroid cancer: genetic evidence for constitutive activation of the
RET/PTC-RAS-BRAF signaling pathway in papillary thyroid carcinoma.
Cancer Res. 7:1454–1457. 2003.PubMed/NCBI
|
|
9
|
Honecker F, Wermann H, Mayer F, et al:
Microsatellite instability, mismatch repair deficiency, and BRAF
mutation in treatment-resistant germ cell tumors. J Clin Oncol.
13:2129–2136. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Bamford S, Dawson E, Forbes S, Clements J,
Pettett R, Dogan A, Flanagan A, Teague J, Futreal PA, Stratton MR
and Wooster R: The COSMIC (Catalogue of Somatic Mutations in
Cancer) database and website. Br J Cancer. 91:355–358.
2004.PubMed/NCBI
|
|
11
|
Wan PT, Garnett MJ, Roe SM, Lee S,
Niculescu-Duvaz D, Good VM, Jones CM, Marshall CJ, Springer CJ,
Barford D and Marais R: Mechanism of activation of the RAF-ERK
signaling pathway by oncogenic mutations of B-RAF. Cell.
116:855–867. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Hoeflich KP, Gray DC, Eby MT, et al:
Oncogenic BRAF is required for tumor growth and maintenance in
melanoma models. Cancer Res. 2:999–1006. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Sumimoto H, Miyagishi M, Miyoshi H, et al:
Inhibition of growth and invasive ability of melanoma by
inactivation of mutated BRAF with lentivirus-mediated RNA
interference. Oncogene. 36:6031–6039. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Pratilas CA and Solit DB: Therapeutic
strategies for targeting BRAF in human cancer. Rev Recent Clin
Trials. 2:121–134. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Gao H, Ouyang X, Banach-Petrosky WA,
Gerald WL, Shen MM and Abate-Shen C: Combinatorial activities of
Akt and B-Raf/Erk signaling in a mouse model of
androgen-independent prostate cancer. Proc Natl Acad Sci USA.
39:14477–14482. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Jeong JH, Wang Z, Guimaraes AS, et al:
BRAF activation initiates but does not maintain invasive prostate
adenocarcinoma. PLoS One. 12:e39492008. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Liu T, Willmore-Payne C, Layfield LJ and
Holden JA: Lack of BRAF activating mutations in prostate
adenocarcinoma: a study of 93 cases. Appl Immunohistochem Mol
Morphol. 2:121–125. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Riely GJ, Politi KA, Miller VA and Pao W:
Update on epidermal growth factor receptor mutations in non-small
cell lung cancer. Clin Cancer Res. 24:7232–7241. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Al-Kuraya K, Schraml P, Sheikh S, et al:
Predominance of high-grade pathway in breast cancer development of
Middle East women. Mod Pathol. 7:891–897. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Choi DH, Shin DB, Lee MH, et al: A
comparison of five immunohistochemical biomarkers and HER-2/neu
gene amplification by fluorescence in situ hybridization in white
and Korean patients with early-onset breast carcinoma. Cancer.
8:1587–1595. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Michaloglou C, Vredeveld LC, Mooi WJ and
Peeper DS: BRAF(E600) in benign and malignant human tumours.
Oncogene. 7:877–895. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Marchetti A, Felicioni L and Buttitta F:
Assessing EGFR mutations. N Engl J Med. 5:526–528. 2006.PubMed/NCBI
|
